Expanding Evidence for Glucagon-Like Peptide-1 Receptor Agonists in Those with Diabetes and Kidney Disease
- 9 April 2026
- journal article
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (5) , 738-740
Abstract
No abstract availableKeywords
Funding Information
- National Heart, Lung, and Blood Institute (K24 HL161414-01A)
- Garabed Eknoyan MD Endowed Professorship
This publication has 10 references indexed in Scilit:
- Cardiovascular-Kidney-Metabolic Medication Eligibility Across National Survey, Community-Based, and Ambulatory Healthcare SamplesJAMA Cardiology, 2026
- Kidney and Survival Outcomes with Semaglutide by CKD Severity in the FLOW TrialClinical Journal of the American Society of Nephrology, 2026
- REMODELing mechanistic trials for kidney disease: a multimodal, tissue-centered approach to understand the renal mechanism of action of semaglutideKidney International, 2025
- GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesityJournal of Clinical Investigation, 2025
- Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 DiabetesNew England Journal of Medicine, 2025
- The effect of GLP ‐1 receptor agonists on circulating inflammatory markers in type 2 diabetes patients: A systematic review and meta‐analysisDiabetes, Obesity and Metabolism, 2025
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 DiabetesNew England Journal of Medicine, 2024
- Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and ObesityDiabetes Care, 2024
- Concordance With Screening and Treatment Guidelines for Chronic Kidney Disease in Type 2 DiabetesJAMA Network Open, 2024
- Moving from Evidence to Implementation of Breakthrough Therapies for Diabetic Kidney DiseaseClinical Journal of the American Society of Nephrology, 2022